You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-CD3 monoclonal antibodies (mAbs)

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Migraine Disorders, Chronic Migraine, Episodic Migraine Trial in Pavia (Monoclonal antibody targeting the CGRP pathway (ligand

Recruiting
  • Migraine Disorders
  • +2 more
  • Monoclonal antibody targeting the CGRP pathway (ligand or receptor) (mAbs)
  • Pavia, Italy
    Headache Science & Neurorehabilitation Center
Nov 23, 2023

Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +9 more
  • Anti-CD30/CD16A Monoclonal Antibody AFM13
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma Trial in Seattle (Bomedemstat, Atezolizumab)

Recruiting
  • Extensive Stage Lung Small Cell Carcinoma
  • Limited Stage Lung Small Cell Carcinoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Mar 30, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

DLBCL Trial in Houston (Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022

Plasma Cell Myeloma Trial in Rochester (Bortezomib, Daratumumab, Dexamethasone)

Recruiting
  • Plasma Cell Myeloma
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 26, 2022

Acute Myeloblastic Leukemia, Acute Lymphoblastic Leukemia, Juvenile Myelomonocytic Leukemia Trial in London (Yttrium-90 labelled

Completed
  • Acute Myeloblastic Leukemia
  • +2 more
  • Yttrium-90 labelled monoclonal antibody against CD66
  • London, United Kingdom
    Great Ormond Street Hospital for Children
Jun 24, 2021

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Cyclophosphamide, Fludarabine Phosphate, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Covid19 Trial in New York (C144-LS and C-135-LS)

Completed
  • Covid19
  • C144-LS and C-135-LS
  • New York, New York
    The Rockefeller University
Aug 2, 2022

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large

Recruiting
  • Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 10, 2022

CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)

Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 11, 2022

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Trial in Seattle (procedure, drug, biological)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  • Bone Marrow Aspiration and Biopsy
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

HIV/AIDS Trial in Orlando, Boston, Houston (PGT121 + VRC07-523LS, PGT121 + VRC07-523LS + PGDM1400)

Completed
  • HIV/AIDS
  • PGT121 + VRC07-523LS
  • PGT121 + VRC07-523LS + PGDM1400
  • Orlando, Florida
  • +2 more
May 6, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Basiliximab, Carmustine, Cytarabine)

Recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Basiliximab
  • +6 more
  • Duarte, California
    City of Hope Medical Center
Jun 16, 2022

DLBCL, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma Trial in Seattle (procedure, drug, biological)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Biopsy
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 12, 2022

Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 Trial in Houston (biological, drug, other)

Active, not recruiting
  • Metastatic Melanoma
  • Stage IV Cutaneous Melanoma AJCC v6 and v7
  • Aldesleukin
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 2, 2022

Inert Non Hodgkin's Lymphoma Trial in Beijing (IBI376, Rituximab)

Recruiting
  • Inert Non Hodgkin's Lymphoma
  • Beijing, China
    Biotherapeutic Department, Chinese PLA General Hospital
Feb 19, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in

Recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +5 more
  • Fresno, California
  • +2 more
Jan 24, 2023

Safety and Efficacy Trial in Suzhou (Ruxolitinib)

Recruiting
  • Safety and Efficacy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Aug 23, 2021

Relapsed and/or Refractory Multiple Myeloma (RRMM) Trial in United States (TAK-981, Mezagitamab, Daratumumab and

Recruiting
  • Relapsed and/or Refractory Multiple Myeloma (RRMM)
  • Scottsdale, Arizona
  • +11 more
Jan 6, 2022

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,

Active, not recruiting
  • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
  • +11 more
  • Atlanta, Georgia
  • +1 more
Apr 18, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial

Active, not recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 3, 2022